• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » OptiNose adds three to operations, regulatory affairs and commercialization

OptiNose adds three to operations, regulatory affairs and commercialization

June 12, 2014
CenterWatch Staff

OptiNose, a global specialty pharmaceuticals company, has announced three appointments to the company's senior management team.

Ramona Lloyd, Ph.D. has joined the company as vice president, Regulatory Affairs and Quality. Lloyd has held executive leadership positions in Regulatory Affairs and Quality with such companies as Sanofi-Aventis, Bristol-Myers Squibb and Johnson & Johnson. She acted as senior vice president of Regulatory Affairs and Safety for ImClone Systems, a wholly-owned subsidiary of Eli Lilly.

Sheila Bergey has joined the company as vice president, Operations & Program Management. Bergey spent 25 years with Johnson & Johnson where she held leadership positions in Operations, Supply Chain and Change Management, including Strategic Planning, Program Management, Information Technology, Process Excellence and Procurement. She founded Saybrook Consulting and was appointed chief operating officer of Lindi Skin, a skin care company in the Philadelphia area. Most recently, Bergey was with MannKind, a bio-pharmaceutical company focused on developing drug-device combination product technologies.

Terrence Terifay has joined the company as senior vice president and chief commercial officer. Most recently, Terifay held commercial leadership positions at Mallinckrodt, including vice president, Marketing and interim general manager, Branded Specialty Pharmaceuticals. Previously, he was the executive vice president, chief operating officer, Synchrony Healthcare Group. He has also held positions of leadership and roles with increasing responsibility at Cephalon, Purdue Pharma and Johnson & Johnson.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing